Flomics
Flomics is a biotechnology company specializing in genomics and liquid biopsy. By integrating Next-Generation Sequencing (NGS) with machine learning, Flomics has developed a liquid biopsy test that provides clinically relevant information for the early detection and management of cancer and other complex diseases from a simple blood sample. The company offers tailored genomics solutions, supporting various research projects from patient screening to large biomarker discovery. Their mission is to enhance clinical practices through innovative, non-invasive testing methods that identify RNA changes associated with disease states.
Flomics
Flomics is a biotechnology company specializing in genomics and liquid biopsy. By integrating Next-Generation Sequencing (NGS) with machine learning, Flomics has developed a liquid biopsy test that provides clinically relevant information for the early detection and management of cancer and other complex diseases from a simple blood sample. The company offers tailored genomics solutions, supporting various research projects from patient screening to large biomarker discovery. Their mission is to enhance clinical practices through innovative, non-invasive testing methods that identify RNA changes associated with disease states.
TL;DR
Headquarters: Barcelona, Spain
Founded: 2018
Product focus: RNA-based liquid biopsy using cfRNA sequencing + ML for multicancer detection and monitoring
Last known funding activity: €1.1M round announced Mar 6, 2024; later crowdfunding €798,502 (Jun–Jul 2024)
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Early cancer detection, disease monitoring, and biomarker discovery using circulating cell-free RNA
Founded
2018
Industry
Biotechnology Research
Tech Stack
Funding Track Record
€1.1M
Round supported by Decelera Ventures, FCR, Histemi Inversiones and the Dr. Rosell Oncology Institute (IOR)
€798,502
Raised from 344 investors via a crowd equity campaign